Cooperation AgreementCooperation Agreement • August 19th, 2022 • Singer Julian D. • Pharmaceutical preparations • Delaware
This Cooperation Agreement (this “Agreement”) is made and entered into as of August 18, 2022 (the “Effective Date”) by and among Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), and each of the parties listed on Exhibit A hereto (each, an “Investor” and collectively, the “Investors” or, with their respective controlled Affiliates, except as noted on Exhibit A, the “Investor Group”). The Company and each of the Investors are each herein referred to as a “party” and collectively, the “parties.”)
JOINT FILING AGREEMENTJoint Filing Agreement • March 28th, 2016 • Singer Julian D. • Radio & tv broadcasting & communications equipment
This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
AMENDED AND RESTATED JOINT FILING AGREEMENTJoint Filing Agreement • September 14th, 2016 • Singer Julian D. • Radio & tv broadcasting & communications equipment
WHEREAS, JDS1, LLC, a Delaware limited liability company (“JDS1”), David S. Oros and John H. Burke are a party to a Joint Filing Agreement (the “Original Agreement”), dated March 28, 2016, with respect to the securities of Aviat Networks, Inc. (the “Company”);
CONSENT AND LIMITED WAIVER TO BOARD REPRESENTATION AND STANDSTILL AGREEMENTConsent and Limited Waiver to Board Representation and Standstill Agreement • November 2nd, 2017 • Singer Julian D. • Electronic computers
This Consent and Limited Waiver to the Board Representation and Standstill Agreement is delivered by Concurrent Computer Corporation, a Delaware corporation (the “Company”), on October 26, 2017 to JDS1, LLC, a Delaware limited liability company (the “Investor”) and Julian D. Singer, in his individual capacity (the “Investor Affiliate,” and together with the Investor, the Investor Affiliate, and the Affiliates and Associates of each of the foregoing, the “Investor Group”). Capitalized terms used but not defined herein shall have the meanings set forth in the Board Representation and Standstill Agreement dated as of August 29, 2016 by and among the Company, the Investor, Investor Affiliate, and Wayne Barr in his individual capacity (the “Standstill Agreement”).
FORM OF NOMINEE INDEMNIFICATION AGREEMENTNominee Indemnification Agreement • March 7th, 2022 • Singer Julian D. • Pharmaceutical preparations • New York
Thank you for agreeing to serve as a nominee for election to the Board of Directors of Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the proxy solicitation that JDS1, LLC, a Delaware limited liability company (the “Indemnifying Party”), is considering undertaking to nominate and elect directors, and present other business, at the Company’s 2022 annual meeting of stockholders, or any other meeting of stockholders held in lieu thereof, and any adjournments, postponements, reschedulings or continuations thereof (the “Solicitation”). Your outstanding qualifications, we believe, will prove a valuable asset to the Company and all of its stockholders. This letter will set forth the terms of our agreement.
Aviat Networks, Inc. Santa Clara, CA 95054Investment Agreement • September 14th, 2016 • Singer Julian D. • Radio & tv broadcasting & communications equipment • Delaware
This letter (this “Agreement”) constitutes the agreement between (a) Aviat Networks, Inc. (“Company”) and (b) JDS1, LLC (“JDS1”) and each of the other related Persons (as defined below) set forth on the signature pages to this Agreement (collectively with JDS1, the “JDS Group”). The JDS Group and each of its Affiliates (as defined below) and Associates (as defined below) are collectively referred to as the “Investors.” Company and the JDS Group are each a “Party” and collectively the “Parties.”
JOINT FILING AGREEMENTJoint Filing Agreement • August 3rd, 2022 • Singer Julian D. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), each of the undersigned hereby agrees that (i) a statement on Schedule 13D with respect to the common stock, $0.001 par value per share (“Common Stock”), of Catalyst Biosciences, Inc., a Delaware corporation, including amendments thereto, shall be filed on behalf of each of the undersigned, and (ii) this Joint Filing Agreement shall be included as an exhibit to such joint filing, provided that, as provided by Rule 13d-1(k)(1)(ii) promulgated under the Exchange Act, no person shall be responsible for the completeness or accuracy of the information concerning the other person making the filing unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrumen
Joint Filing AgreementJoint Filing Agreement • October 26th, 2021 • Singer Julian D. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Catalyst Biosciences, Inc., and that this Joint Filing Agreement may be included as an Exhibit to such joint filing. This Joint Filing may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
AMENDED AND RESTATED JOINT FILING AGREEMENTJoint Filing Agreement • February 23rd, 2022 • Singer Julian D. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), each of the undersigned hereby agrees that (i) a statement on Schedule 13D with respect to the common stock, $0.001 par value per share (“Common Stock”), of Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), including amendments thereto, shall be filed on behalf of each of the undersigned, and (ii) this Joint Filing Agreement shall be included as an exhibit to such joint filing, provided that, as provided by Rule 13d-1(k)(1)(ii) promulgated under the Exchange Act, no person shall be responsible for the completeness or accuracy of the information concerning the other person making the filing unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and th
JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • July 28th, 2016 • Singer Julian D. • Electronic computers
WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Concurrent Computer Corporation, a Delaware corporation (the “Company”);
Joint Filing AgreementJoint Filing Agreement • July 23rd, 2019 • Singer Julian D. • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Catalyst Biosciences, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • March 7th, 2022 • Singer Julian D. • Pharmaceutical preparations
WHEREAS, this Joint Filing and Solicitation Agreement (the “Agreement”) amends and restates the Group Agreement dated as of February 22, 2022 entered into by certain of the parties hereto, pursuant to which the parties named therein formed a “group” (as contemplated by Section 13(d) of the Securities Exchange Act of 1934, as amended);
